Molecular typing is based on molecular genetic screening and is not still routinely offered. Molecular subtypes and immunohistochemical surrogate markers in the tumors (HR, HER2, triple negative) correlate in about 70%. The differentiation of luminal A and B subtypes by HR position and prolifera